1 / 15

Comprehensive Guidelines for Accelerated Partial Breast Irradiation Patient Selection

This document outlines the patient evaluation process, types of APBI, current guidelines, study results, and recurrence rates of patients undergoing APBI. It presents acceptable and not acceptable criteria for patient selection based on age, tumor size, histology, and other factors, along with future recommendations.

kaye-mcintyre
Download Presentation

Comprehensive Guidelines for Accelerated Partial Breast Irradiation Patient Selection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD

  2. Patient Evaluation • Multidisciplinary; before surgery • Breast Surgeon • Radiation Oncologist • Medical Oncologists

  3. Types of APBI • Interstitial • Intraoperative • Electron • 50 Kv • Balloon cavitary • Mammosite • Contura • Savi • External Beam • 3D conformal • IMRT

  4. Current Guidelines- Old • ASBS - 2005 • ABS - 2007 • European Collaborative Group - 2009 • ACRO - 2008 • ASTRO- 2009

  5. Additional Studies • At least 5 randomized trials • Short follow-up • Outdated or nonstandard technique • Lack of power • At least 41 non randomized trials • Many with at least 10 year follow-up

  6. Clinical Trial Results • ASBS Mammosite Registry Trial • 44 month follow-up on first 400 cases. • Cancer specific survival of 100% • Local recurrence rate between 0-2.65% • DCIS Phase II Clinical Study • 15 month follow-up on 100 patients • 3% local recurrence rate

  7. Retrospective review of 330 analytic cases of breast cancer treated with accelerated partial breast irradiation from 2006 to present Accelerated Partial Breast Radiation Recurrence rate study(QI 2013 4-6)Tonya Echols Cole, Md& TerrI Richardson, RHIA,CTR 330 APBI procedure 72% (239) were invasive 28% (91) were DCIS

  8. Recurrences • 14 total recurrences ( 4.2%) • 7 Local (2.1%) • 3 Regional (0.9%) • 4 Distant (1.2%) • Median time to recurrence was 53 months

  9. Local Recurrences • 7 local recurrences 2.1% recurrence rate All patients were >50 yrs. old All tumors <3cm • 3 were DCIS or 3/91 or 3.3% • 2 of the 3 did not take Tamoxifen (pt. refusal or medically contraindicated.) • All were ER+ • 4 were invasive 4/239 or 1.7% • 1 was triple negative 2 were triple +

  10. Regional Recurrences • 3 regional recurrences 3/330 ( 0.9%) • All invasive cancer <3cm • All >60 yrs. old • 2 were triple -, 1ER+, Her2+ • All had 3 lymph nodes examined

  11. Distant recurrences • 4 Distant recurrences 4/330 (1.2%) • 75% ¾ were invasive • All >50 yrs. old • All tumors <3cm • All were ER+ • All received hormonal therapy • 1 received chemotherapy • 25% (1/4) DCIS • Was ER -

  12. Conclusions • Local recurrence rates for patients treated with accelerated partial breast radiation therapy at DMC are comparable to published data. • There was no group or subset found to be at increased risk of recurrence.

  13. Acceptable • Age > 50 • Size < 3 cm • Histology All invasive subtypes and DCIS • ER Positive or negative • Margins Negative • LVI Not present • Nodal status negative

  14. Not acceptableOutside of a clinical Trial Microscopically multifocal >3cm EIC > 3cm Margins + Nodal surgery- not performed. BRCA + • Node positive • Tumors > 3cm including DCIS • Extensive LVSI • Neoadjuvant chemo • Age <45 • Multicentric

  15. Future Directions • Recommendations should be updated annually as new results from prospective randomized trials are released.

More Related